Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)

NCT03944252 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Anal Carcinoma

Interventions

DRUG: Avelumab
DRUG: Cetuximab

Sponsor

Gruppo Oncologico del Nord-Ovest